Publications by authors named "P Marcolin"

Objective: We aim to perform a systematic review and meta-analysis to analyze the efficacy and safety of low-cost meshes compared to polypropylene meshes for IHR.

Methods: We searched Pubmed, Embase, Cochrane, and Web of Science for randomized controlled trials (RCTs) comparing low-cost and standard meshes for IHR. Low-cost mesh was defined as a material non-designed for medical use.

View Article and Find Full Text PDF

Purpose: Laparoscopic intracorporeal rectus aponeuroplasty (LIRA), emerged as a method that combines benefits from minimally invasive and abdominal wall reconstruction with defect closure, restoring the midline without tension by folding the posterior aponeurosis of both abdominal rectus muscles and using intraperitoneal mesh repair. We aimed to perform a systematic review of the existing evidence on LIRA results and potential applications.

Source: A thorough search of Cochrane Central, Scopus, SciELO, LILACS, and PubMed/MEDLINE, focusing on studies that explored LIRA's possible applications and results was performed.

View Article and Find Full Text PDF

Bile acid sequestrants (BASs) have often been used for bile acid diarrhea (BAD) but carry a high risk of adverse events. New generations of BASs show promising results; however, their efficacy remains unclear. This systematic review and meta-analysis was conducted using PubMed, Cochrane, and Embase to assess randomized controlled trials (RCTs) published up to November 2023 to retrieve studies that measured the parameters before and after the administration of BASs.

View Article and Find Full Text PDF
Article Synopsis
  • - Ruxolitinib, a JAK1/JAK2 inhibitor, shows improved effectiveness in managing polycythemia vera (PV) compared to best available therapy (BAT), with higher rates of hematocrit control and treatment response, especially in patients resistant to hydroxyurea.
  • - The analysis of six studies with over 1,000 patients found that ruxolitinib also significantly improved symptoms related to myeloproliferative neoplasms.
  • - While ruxolitinib reduces thromboembolism risk, it is linked to increased rates of anemia, herpes zoster infections, and nonmelanoma skin cancer.
View Article and Find Full Text PDF